Novel Therapeutics May Inhibit Ceramide Production in LCFAOD

New therapeutic strategies currently in development could inhibit the production of ceramides, a lipid molecule implicated in metabolic disease and long chain fatty acid oxidation disorders (LCFAOD).

Scott Summers, PhD Credit: INFORM

Scott Summers, PhD, reviewed how an overaccumulation of fat-derived molecules, as seen in obesity, physical inactivity, and LCFAODs, contributes to the tissue dysfunction that underscores many common metabolic diseases, including diabetes. He presented this at the International Network for Fatty Acid Oxidation Research and Management (INFORM) Virtual Meeting on October 27-28, 2021.